AstraZeneca will pay $175 in cash and shares for Alexion, a Boston-based drugmaker that specializes in rare disease treatments. AstraZeneca will pay around $175 per share for Alexion, through a ...

Alexion is to buy rare diseases biotech Syntimmune and its experimental drug for a rare kind of anaemia, in a deal worth up $1.2 billion. The companies have signed a deal where Alexion will pay $ ...

The US Food and Drug Administration (FDA) has approved Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab-cwvz) to ...

Alexion, AstraZeneca Rare Disease has received the US Food and Drug Administration's (FDA) approval for Voydeya (danicopan) ...

Shares of Alexion Pharmaceuticals (ALXN) were down in afternoon trading Wednesday after the company agreed to acquire Synageva Biopharma for $8.4 billion. Shares of Alexion Pharmaceuticals (ALXN ...

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life ...

Alexion has made its name by developing Soliris (eculizumab), first launched in 2007, and is on track to earn $2.5 billion this year through treating two life-threatening and ultra-rare disorders ...

Sabastian Niles joined the CRM giant in July, giving up his career as one of the nation's foremost legal advisers on M&A and shareholder activism.

Enter Alexion (Nasdaq: ALXN), a biotechnology group specialising in ultra-rare ailments. Alexion's blockbuster Soliris treats PNH and aHUS, which are life-threatening blood disorders. Don't miss ...

Lights, camera, Alexion! Fresh off earning FDA approval for its drug Ultomiris to treat certain adults with neuromyelitis optica spectrum disorder (NMOSD), AstraZeneca’s rare disease unit has ...

Alexion Pharmaceuticals, AstraZeneca’s rare disease unit, shined a light on neuromyelitis optica spectrum disorder (NMOSD), a severe neurological disease, in a short film that debuted Thursday. While ...

Benzinga's Insider Buys Of The Week: Alexion Pharmaceuticals, Sohu.com And More Short-Sellers Favor These 2 Biotech Stocks In July Biotech In The Earnings Spotlight: Amgen, Celgene, Gilead ...